A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
Regional troops have secured the presidential palace in the Gambia's capital but there are fears the former leader has raided state coffers.
The police officer was shot in the arm at a petrol station on the Crumlin Road, but is in a stable condition.
Temperatures tumbling again tonight with a widespread sharp frost and lows of -5C or -6C and icy spots in places